11-β-羟基雄烯二酮(4-androsten-11β-ol-3,17-dione)主要存在于肾上腺中,而11β-羟化酶在肾上腺组织中有存在,但在卵巢组织中不存在。11-β-羟基雄烯二酮是一种11β-羟基类固醇脱氢酶(11βHSD)同工酶抑制剂。随着4-雄烯二酮的增加,在测量血浆11-β-羟基雄烯二酮水平时,可以区分高雄激素血症的肾上腺或卵巢起源。
靶点Human Endogenous Metabolite
体外研究为了证明这种转化是由CYP17A1的裂解酶活性催化完成的,在LNCaP细胞系中检测21-脱氧皮质醇(21dF)和21-脱氧皮质酮(21dE)。转染CYP17A1后,11-β-羟基雄烯二酮(11OHA4)途径代谢物增加,CYP17A1将21dF转化为11-β-羟基雄烯二酮和11-酮孕酮(11KP4),将21dE转化为11-酮孕酮。
体内研究在21-羟化酶缺乏症、库欣综合征及肾上腺源性高雄激素血症中,血浆11-β-羟基雄烯二酮水平非常高;而在先天性11-羟化酶缺乏和肾上腺功能不全中,则非常低。因此,在血浆4-雄烯二酮升高的情况下,测量血浆11-β-羟基雄烯二酮水平有助于确定高雄激素血症的肾上腺或卵巢起源。
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
11beta-羟基睾酮 | 11β-hydroxytestosterone | 1816-85-9 | C19H28O3 | 304.43 |
瑞索可托 | 4-pregnen-17, 21-diol-3, 20-dione | 76675-97-3 | C22H32O4 | 360.494 |
雄烯二酮 | Androstenedione | 63-05-8 | C19H26O2 | 286.414 |
氢化可的松 | HYDROCORTISONE | 50-23-7 | C21H30O5 | 362.466 |
(11beta,20S)-11,17,20,21-四羟基孕甾-4-烯-3-酮 | 11β,17α,20R,21-tetrahydroxypregn-4-en-3-one | 116-58-5 | C21H32O5 | 364.482 |
肾上腺甾酮 | adrenosterone | 382-45-6 | C19H24O3 | 300.398 |
醋酸氢化可的松 | hydrocortisone acetate | 50-03-3 | C23H32O6 | 404.503 |
11beta,17,21-三羟基孕甾-4-烯-3,20-二酮 21-甲烷磺酸酯 | Cortisol 21-mesylate | 6677-96-9 | C22H32O7S | 440.558 |
—— | 5-androstene-3,11,17-trione 3,17-bisethyleneketal | 13872-18-9 | C23H32O5 | 388.504 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | 6β,11β-dihydroxy-4-androstene-3,17-dione | 54668-66-5 | C19H26O4 | 318.413 |
11beta-羟基睾酮 | 11β-hydroxytestosterone | 1816-85-9 | C19H28O3 | 304.43 |
(8S,9S,10R,11S,13S,14S,17S)-11,17-二羟基-10,13,17-三甲基-2,6,7,8,9,11,12,14,15,16-十氢-1H-环戊并[a]菲-3-酮 | 11β-hydroxy-17α-methyltestosterone | 1043-10-3 | C20H30O3 | 318.456 |
11beta,17alpha-二羟基-4-孕烯-3,20-二酮 | 21-deoxycortisol | 641-77-0 | C21H30O4 | 346.467 |
肾上腺甾酮 | adrenosterone | 382-45-6 | C19H24O3 | 300.398 |
9-去氢睾酮 | 17β-Hydroxy-androsta-4,9(11)-dien-3-on | 2398-99-4 | C19H26O2 | 286.414 |
—— | 9α,11α-epoxy-4-androstene-3,17-dione | 22614-34-2 | C19H24O3 | 300.398 |
—— | 4-androstene-3,6,11,17-tetraone | 79037-18-6 | C19H22O4 | 314.381 |
雄甾-4,9(11)-二烯-3,17-二酮 | androst-4,9(11)-dien-3,17-dione | 1035-69-4 | C19H24O2 | 284.398 |
—— | (1R,2S,10S,11S,15S,17R)-4-hydroxy-2,15-dimethyl-18-oxapentacyclo[8.8.0.01,17.02,7.011,15]octadec-6-ene-5,14-dione | 182202-98-8 | C19H24O4 | 316.397 |
—— | methyl (2Z)-2-[(1R,3R,5S,9S,10S,14S)-5,14-dimethyl-6-oxo-14-(2-oxoethyl)-2-oxatetracyclo[8.4.0.01,3.05,9]tetradecan-13-ylidene]acetate | 182202-99-9 | C20H26O5 | 346.423 |
—— | 5α-androstan-11β-ol-3,17-dione | 599-11-1 | C19H28O3 | 304.43 |
—— | (3β,5α,11β)-3,11-dihydroxyandrostan-17-one | 116698-46-5 | C19H30O3 | 306.445 |
11β-羟基本胆烷醇酮 | 11β-hydroxyetiocholanolone | 739-26-4 | C19H30O3 | 306.445 |
11β-羟基雄甾酮 | (3R,5S,8S,9S,10S,11S,13S,14S)-3,11-dihydroxy-10,13-dimethyl-tetradecahydro-2H-cyclopenta[a]phenanthren-17(14H)-one | 57-61-4 | C19H30O3 | 306.445 |
—— | (3β,5β,11β)-3,11-dihydroxyandrostan-17-one | 3461-66-3 | C19H30O3 | 306.445 |
—— | methyl (2Z)-2-[(1R,3R,5S,9S,10S,14S)-14-ethenyl-5,14-dimethyl-6-oxo-2-oxatetracyclo[8.4.0.01,3.05,9]tetradecan-13-ylidene]acetate | 182203-05-0 | C20H26O4 | 330.424 |